Sanofi has partnered with Parisian deeptech Aqemia to develop new drugs using a platform based on quantum-inspired physics and generative artificial intelligence. The partnership, signed on December 5, could bring in up to $140 million to Aqemia.
Aqemia, founded in 2019, created a platform that uses AI to invent new molecules and a quantum physics engine to predict their disease activity. Unlike other AI-driven platforms, Aqemia generates chemical experimental data in-house by performing highly efficient physical calculations from the start of each research project.
The collaboration between Sanofi and Aqemia will cover all stages of drug discovery, from the identification of molecules to the selection of drug candidates for development. Sanofi will then take care of R&D and marketing.
Aqemia previously worked with Sanofi in 2020 to find a treatment for SARS-CoV-2. The start-up also collaborates with other laboratories and has raised three funds since its creation.
 Sophie de Duiéry
|
06/12/2023 | 
